[Skip to Content]
[Skip to Content Landing]
October 26, 1963


JAMA. 1963;186(4):17-18. doi:10.1001/jama.1963.03710040001001

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Committee Decides Krebiozen Ineffective: NCI Clinical Test Ruled Out.  —A special advisory committee of 22 cancer specialists decided unanimously that krebiozen showed no value in the treatment of cancer, and recommended that the National Cancer Institute hold no clinical trial of the controversial product.Kenneth M. Endicott, MD, head of the NCI, agreed with the findings and forwarded his recommendation to the HEW Secretary.The physicians committee was appointed by NCI to evaluate 504 cases of patients treated with krebiozen. The cases were selected by sponsors of krebiozen as those showing the efficacy of the product. The Food and Drug Administration investigated all of the cases and provided as much information from physicians and hospital files as possible.The committee said that of the total 504 cases, 288 fulfilled the necessary conditions so that the effects of krebiozen could be evaluated. Of these, 273 showed no significant regression. Two of

First Page Preview View Large
First page PDF preview
First page PDF preview